Pharma News

The European Medicines Agency’s (EMA’s) Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion, recommending the granting of a conditional marketing authorisation for the medicinal product loncastuximab tesirine (Zynlonta), intended for the treatment of adult patients with diffuse large B-cell lymphoma and high-grade B-cell lymphoma.

The applicant for this medicinal product is ADC Therapeutics (NL) B.V.

it may be the most baffling quirk of COVID: What manifests as minor, flu-like symptoms in some individuals spirals into severe disease, disability, or even death in others. A new paper published in Nature may explain the genetic underpinnings of this dichotomy.

Shilpa medicare gets CDSCO approval for Tranexamic Acid Spray, Hemostatic Spray. The product is protected by granted patents in India till 2037 and in US, Australia, Russia and South Africa till 2038. Shilpa is continuously pursuing patent prosecution in other countries and for further protection.

This two-day event was held on September 15th and 16th.It was a uniquely planned event, where the focus was on understanding how organisations can build an apt strategy for achieving manufacturing excellence and using digital and automation as tools for modernising.
The conference ensured continuous engagement of the audience & speakers through various discussions in the form of Case-Study solving, Panel Discussion and group discussions to understand and create a viable Business Strategy for exponential growth.

BioIVT, a leading provider of biospecimens, research models and services for drug and diagnostic development announced the launch of its Good Manufacturing Practice (GMP-) grade VivoSTART  leukopaks. Leukopaks contain concentrated white blood cells and are used to research and manufacture cell and gene therapies.

Lower immunity and recurring infections are common in type 1 and type 2 diabetes. Researchers at Karolinska Institutet now show that the immune system of people with diabetes has lower levels of the antimicrobial peptide psoriasin, which compromises the urinary bladder’s cell barrier, increasing the risk of urinary tract infection. The study is published in Nature Communications.

Sitagliptin, a new variant of medicines for diabetes, launched at affordable prices for all under the Pradhan Mantri Bhartiya Janaushadhi Pariyojana. PMBI included new variants of medicines Sitagliptin and its combination in its all Jan Aushdhi Kendras.

Sitagliptin is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. All these variants are available at 60% to 70% lesser prices than branded variants.

BridgeBio Pharma, Inc , a commercial-stage biopharmaceutical company that focuses on genetic diseases and cancers, and Sentynl Therapeutics, Inc. (Sentynl), a U.S.-based biopharmaceutical company focused on bringing innovative therapies to patients living with rare diseases owned by Zydus Lifesciences Ltd. announced the European Commission (EC) has granted marketing authorization for NULIBRY  (fosdenopterin) for Injection as the first therapy for the treatment of patients with molybdenum cofactor deficiency (MoCD) Type A.

Because of their highly active metabolism, many tumors are susceptible to a special type of cell death, ferroptosis. Nevertheless, cancer cells often manage to escape this fate. Scientists at the German Cancer Research Center have now discovered a new mechanism by which normal as well as cancer cells protect themselves against ferroptosis. Knowledge of these molecular connections could provide new starting points for the treatment of tumors.